Rytary
NDC Package 60846-663-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Rytary is a medication used to treat the symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. Marketed by Amneal Pharmaceuticals Llc, this product is identified by NDC 60846-663 and is authorized under FDA application NDA203312.

Identification & Billing

NDC Package Code
60846-663-01
Package Description
100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
60846-663
11-Digit Billing Format
60846066301

Clinical Specifications

Proprietary Name
Rytary
Dosage Form
-
Usage Information
This medication is used to treat the symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Regulatory & Marketing

Labeler Name
Amneal Pharmaceuticals Llc
FDA Application #
NDA203312
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-25-2025
End Marketing Date
12-15-2025
Listing Expiration
12-15-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60846-663-01 identifies a specific commercial package of 100 capsule, extended release in 1 bottle of Rytary, labeled by Amneal Pharmaceuticals Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amneal Pharmaceuticals Llc on June 25, 2025. The current certification is valid through December 15, 2025.

What are the primary indications for this medication?

This medication is used to treat the symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

How is this Amneal Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60846066301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60846-663-01
11-Digit CMS (5-4-2)
60846-0663-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.